<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacologic agents for the treatment of HIV-DSPN</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacologic agents for the treatment of HIV-DSPN</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacologic agents for the treatment of HIV-DSPN</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Dosage and administration in adults</td> <td class="subtitle1">Avoid or use caution in:</td> <td class="subtitle1">Common adverse effects</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Preferred agents for most patients</td> </tr> <tr> <td class="indent1">Gabapentin*</td> <td> <p><strong>IR:</strong> Start with 100 to 300 mg orally 1 to 3 times daily. Can increase gradually to 800 mg 3 times daily (2400 mg daily in 2 or 3 divided doses).</p> <strong>ER:</strong> Start with 300 mg orally once daily at bedtime. Can increase gradually to 900 mg to 2400 mg once daily. </td> <td> <ul> <li>Older adults: Initiate at lowest dose and titrate more gradually</li> <li>History of substance use</li> </ul> </td> <td> <p><strong>Neurologic:</strong> Dizziness, drowsiness, ataxia, confusion.</p> <p><strong>Gastrointestinal:</strong> Nausea, diarrhea.</p> <strong>Other:</strong> Weight gain, peripheral edema, risk for misuse and addiction. </td> </tr> <tr> <td class="indent1">Pregabalin*</td> <td> <p><strong>IR:</strong> Start with 25 to 75 mg orally twice daily. Can increase gradually to 75 to 150 mg orally twice daily.</p> <strong>ER:</strong> Start with 165 mg orally once daily. Can increase gradually to 330 mg orally once daily. </td> <td> <ul> <li>Older adults: Initiate at lowest dose and titrate more gradually</li> <li>History of substance use</li> </ul> </td> <td> <p><strong>Neurologic:</strong> Dizziness, drowsiness, ataxia, confusion.</p> <p><strong>Gastrointestinal:</strong> Nausea, diarrhea.</p> <strong>Other:</strong> Weight gain, peripheral edema, risk for misuse and addiction. </td> </tr> <tr> <td class="indent1">Duloxetine</td> <td>Start with 30 mg orally once daily for one week. Can increase to 120 mg orally once daily thereafter.</td> <td> <ul> <li>Hepatic impairment or severe kidney impairment</li> <li>Angle-closure glaucoma</li> </ul> </td> <td> <p><strong>Neurologic:</strong> Insomnia, dizziness, fatigue.</p> <p><strong>Gastrointestinal:</strong> Nausea, dry mouth, constipation.</p> <strong>Other:</strong> Sexual dysfunction. </td> </tr> <tr> <td class="indent1">Tricyclic antidepressants (amitriptyline; nortriptyline)<sup>¶</sup></td> <td>Start with 10 to 25 mg orally daily at bedtime. Can increase gradually to 75 to 100 mg orally once daily at bedtime.</td> <td> <ul> <li>Older adults: Typically avoided; if used, initiate at lowest dose and titrate more gradually</li> <li>Cardiovascular disease, conduction abnormalities</li> <li>Autonomic dysfunction</li> <li>Seizures</li> <li>Glaucoma</li> </ul> </td> <td> <p><strong>Antihistaminic:</strong> Dizziness, drowsiness, confusion, increased appetite.</p> <p><strong>Anticholinergic:</strong> Dry mouth, constipation, urinary retention, blurred vision.</p> <p><strong>Cardiovascular:</strong> Orthostatic hypotension, prolonged QT interval, cardiac arrhythmias.</p> <strong>Other:</strong> Sexual dysfunction, dangerous in overdose. </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Alternative agents for patients who would like to avoid oral medications<sup>Δ</sup></td> </tr> <tr> <td class="indent1"> <p>Capsaicin patch 8%</p> <strong>NOTE:</strong> Administered by health care provider in a clinical setting and monitored for up to 2 hours after treatment </td> <td>Apply patch to most painful areas of the feet for 30 minutes. Up to 4 patches may be applied in a single application. Treatment may be repeated every 3 months as needed for return of pain (do not apply more frequently than every 3 months). Area should be pretreated with a topical anesthetic prior to patch application.</td> <td> <ul> <li>Sensitive skin or chronic skin disorders</li> <li>Do not use on abraded skin</li> </ul> </td> <td> <p>Application site burning, pain, erythema, pruritus.</p> Local pain and irritation may be intolerable. </td> </tr> <tr> <td class="indent1">Lidocaine patch 5%</td> <td>Apply 1 to 3 patches to most painful areas of the feet for 12 hours. Remove for a period of 12 hours before reapplication.</td> <td> <ul> <li>Sensitive skin or chronic skin disorders</li> <li>Do not use on abraded skin</li> </ul> </td> <td>Mild to moderate irritation at application site.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Other alternative agents</td> </tr> <tr> <td class="indent1">Tramadol</td> <td>Start with 37.5 mg orally every 6 hours, as needed for breakthrough pain.</td> <td> <ul> <li>History or risk of substance use</li> <li>Older adults</li> <li>Frail patients who are at risk of falls</li> <li>Kidney or hepatic impairment</li> <li>Seizures</li> </ul> </td> <td> <p>Side-effects are similar to other opioids including risks of overdose and opioid use disorder.</p> Added risk of seizures due to drug interactions. </td> </tr> </tbody></table></div><div class="graphic_lgnd">Preferred oral agents for HIV-DSPN symptom management are initiated at a low dose to minimize adverse effects and titrated in small increments over several weeks based upon efficacy and tolerability. When stopping therapy, dose should be tapered over 1 week or more to reduce the risk of withdrawal symptoms.</div><div class="graphic_footnotes"><p>HIV-DSPN: human immunodeficiency virus-associated distal symmetric polyneuropathy; IR: immediate release; ER: extended release.</p>
<p>* Requires dose adjustment in kidney impairment; refer to Lexicomp monographs.</p>
<p>¶ Nortriptyline is less sedating and has fewer anticholinergic side effects than amitriptyline.</p>
Δ Also used in combination with oral therapies for reducing medication load or as an alternative for patients with contraindications to systemic therapies.</div><div class="graphic_reference">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 138451 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
